Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02951871
Other study ID # 69HCL16_0719
Secondary ID
Status Completed
Phase N/A
First received October 31, 2016
Last updated November 8, 2016
Start date January 2000
Est. completion date July 2016

Study information

Verified date October 2016
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority France: Commission nationale de l'informatique et des libertés
Study type Observational

Clinical Trial Summary

Background.Although the life expectancy of patients with FL has recently increased, notably since the introduction of rituximab in combination with chemotherapy, little is known regarding the precise causes of patients death. Patients and methods'. This study describes the different causes of death in FL patients among followed since 2000 at Lyon University Hospital, centre Léon Bérard and Mayo Clinic. The causes of death will be classified as related to lymphoma progression, treatment-related toxicity (including TRM and secondary myelodysplastic syndrome/acute myeloid leukemia), secondary neoplasias, or other.


Recruitment information / eligibility

Status Completed
Enrollment 237
Est. completion date July 2016
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- FL patients

- patients recorded as deceased

Exclusion Criteria:

-Other diagnosis than FL

Study Design

Time Perspective: Retrospective


Related Conditions & MeSH terms


Locations

Country Name City State
France Centre hospitalier Lyon sud Pierre Bénite Rhône Alpes

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary overall survival (OS) OS length was calculated from the date of diagnosis to the date of death No